- Home>
- Journal Watch
- >
- tamoxifen
Search for tamoxifen in all Journal Watch editions
Physician-authored summaries on the latest research on tamoxifen, editorials on tamoxifen, and perspectives on tamoxifen - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 221 results - Relevance
- Date
You searched for: tamoxifen
-
Tamoxifen Effective for Ductal Carcinoma in Situ
- March 27, 2012
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
In women with estrogen receptor–positive disease, adjuvant tamoxifen reduced risk for subsequent breast cancer.- Reviewing:
- Allred DC et al., J Clin Oncol 2012 Mar 5;:
-
Adjuvant Letrozole Continues to Best Tamoxifen for Early Breast Cancer
- November 15, 2011
- William J. Gradishar, MD
- Oncology and Hematology
Letrozole monotherapy was better than tamoxifen monotherapy; sequential letrozole and tamoxifen were not better than letrozole alone.- Reviewing:
- Regan MM et al., Lancet Oncol 2011 Nov; 12:1101.
-
Breast Density: A Marker of Tamoxifen's Preventive Benefit?
- June 14, 2011
- William J. Gradishar, MD
- Oncology and Hematology
Tamoxifen-associated reductions in mammographic breast density predicted breast cancer risk reduction.- Reviewing:
- Cuzick J et al., J Natl Cancer Inst 2011 May 4; 103:744.
-
Safety of Tamoxifen vs. an Aromatase Inhibitor as Adjuvant Therapy for Breast Cancer
- February 10, 2011
- Andrew M. Kaunitz, MD
- Women's Health
An international randomized trial shows differing safety profiles for tamoxifen and exemestane.- Reviewing:
- van de Velde CJH et al., Lancet 2011 Jan 22; 377:321.
-
Radiotherapy and Tamoxifen for Ductal Carcinoma in Situ
- January 18, 2011
- Henry Mark Kuerer, MD, PhD, FACS
- Oncology and Hematology
Following local excision, radiotherapy had long-lasting benefits and tamoxifen had small absolute benefits for breast cancer outcomes.- Reviewing:
- Cuzick J et al., Lancet Oncol 2011 Jan; 12:21. Silverstein MJ and Lagios MD., J Natl Cancer Inst Monogr 2010; 2010:193. Pinder SE et al., Br J Cancer 2010 Jun 29; 103:94. Eng-Wong J et al., J Natl Cancer Inst Monogr 2010; 2010:200.
-
Consequences of Factor V Leiden Mutation in Patients Treated with Adjuvant Tamoxifen
- July 20, 2010
- William J. Gradishar, MD
- Oncology and Hematology
FVL mutation was associated with markedly increased risk for thrombotic events in breast cancer patients who received adjuvant tamoxifen.- Reviewing:
- Garber JE et al., J Natl Cancer Inst 2010 Jul 7; 102:942.
-
Tamoxifen-Associated Risk for Thromboembolism: Importance of Factor V Leiden Mutation
- July 8, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Clinicians should consider testing for thrombophilic mutations before prescribing adjuvant therapy with tamoxifen for patients with breast cancer.- Reviewing:
- Garber JE et al., J Natl Cancer Inst 2010 Jun 16;: Cuzick J., J Natl Cancer Inst 2010 Jun 16;:
-
Revisiting Breast Cancer Outcomes in Concomitant Users of Tamoxifen and Selective Serotonin Reuptake Inhibitors Free
- May 13, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Poor tamoxifen adherence among SSRI users, rather than inhibition of CYP2D6, might account for unfavorable breast cancer outcomes.- Reviewing:
- Dezentjé VO et al., J Clin Oncol 2010 May 10; 28:2423.
-
Tamoxifen vs. Raloxifene for Breast Cancer Chemoprophylaxis: Longer-Term Data
- May 13, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Raloxifene was less toxic; tamoxifen was slightly more effective.
CME Exam- Reviewing:
- Vogel VG et al., Cancer Prev Res 2010 Apr 19;:
-
More Evidence That Tamoxifen Is Underused for Primary Breast Cancer Prevention
- April 8, 2010
- Diane E. Judge, APN/CNP
- Women's Health
Only a small fraction of women who have favorable tamoxifen risk-benefit profiles receive the agent prophylactically.- Reviewing:
- Waters EA et al., Cancer Epidemiol Biomarkers Prev 2010 Feb; 19:443.
-
Do Selective Serotonin Reuptake Inhibitors Attenuate Tamoxifen's Benefits in Breast Cancer Survivors?
- March 4, 2010
- Andrew M. Kaunitz, MD
- Women's Health
Paroxetine was associated with excess mortality in breast cancer survivors who were receiving tamoxifen as adjuvant therapy.- Reviewing:
- Kelly CM et al., BMJ 2010 Feb 8; 340:c693. Andersohn F and Willich SN., BMJ 2010 Feb 8; 340:c783.
-
Paroxetine Use Negates Benefits of Tamoxifen in Women with Breast Cancer
- February 18, 2010
- Paul S. Mueller, MD
- General Medicine
Paroxetine inhibits conversion of tamoxifen to its active metabolite.
CME Exam- Reviewing:
- Kelly CM et al., BMJ 2010 Feb 8; 340:c693.
-
CYP2D6 Polymorphisms and Response to Tamoxifen
- October 27, 2009
- Virginia Kaklamani, MD, DSc
- Oncology and Hematology
Breast cancer patients with genotypes corresponding to normal CYP2D6 enzyme activity achieved better outcomes than those with diminished or no activity.- Reviewing:
- Schroth W et al., JAMA 2009 Oct 7; 302:1429.
-
Tamoxifen: An Intracellular Target for Treatment of Mania Free
- May 5, 2008
- Steven Dubovsky, MD
- Psychiatry
Another small, positive study for a drug that alters intracellular dynamics- Reviewing:
- Yildiz A et al., Arch Gen Psychiatry 2008 Mar; 65:255.
-
Aromatase Inhibitors in Preventing Breast Cancer Recurrence After 5 Years of Tamoxifen
- May 1, 2008
- Andrew M. Kaunitz, MD
- Women's Health
In women with hormone receptor–positive breast cancer who have completed therapy with tamoxifen, adjuvant therapy with an aromatase inhibitor improved disease-free survival.- Reviewing:
- Muss HB et al., J Clin Oncol 2008 Apr 20; 26:1956. Goss PE et al., J Clin Oncol 2008 Apr 20; 26:1948. Mamounas EP et al., J Clin Oncol 2008 Apr 20; 26:1965. Lin NU and Winer EP., J Clin Oncol 2008 Apr 20; 26:1919.
-
To Avert Tamoxifen-Associated Endometrial Polyps, LNG-IUS Could Be the Answer Free
- January 24, 2008
- Sandra Ann Carson, MD
- Women's Health
The levonorgestrel intrauterine system prevented the occurrence of endometrial polyps in women taking tamoxifen.- Reviewing:
- Chan SSC et al., BJOG 2007 Dec; 114:1510.
-
Anastrozole vs. Tamoxifen in Early Breast Cancer: A Long-Term Update
- January 24, 2008
- Allan S. Brett, MD
- General Medicine
After 5 years of therapy and 3 years of follow-up, disease recurrence was diminished by anastrozole, but overall mortality was the same in the two groups.- Reviewing:
- The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group., Lancet Oncol 2008 Jan; 9:45.
-
Tamoxifen for Mania: Maybe It’s Not Just for Breast Cancer Free
- November 5, 2007
- Jonathan Silver, MD
- Psychiatry
Results from a small pilot study are promising.- Reviewing:
- Zarate CA Jr et al., Bipolar Disord 2007 Sep; 9:561.
-
Switching from Tamoxifen to Exemestane in Estrogen-Receptor–Positive Breast Cancer Free
- March 13, 2007
- Bruce Soloway, MD
- General Medicine
The disease-free survival rate increased significantly among women who made the switch.- Reviewing:
- Coombes RC et al., Lancet 2007 Feb 17; 369:559-70.
-
Letrozole or Tamoxifen for Initial Adjuvant Therapy in Breast Cancer? Free
- March 12, 2007
- William J. Gradishar, MD
- Oncology and Hematology
Long-term findings continue to support the conclusion that letrozole provides additional benefit over tamoxifen.- Reviewing:
- Coates AS et al., J Clin Oncol 2007 Feb 10; 25:486-92.
Sort by:
Items 1 to 20 of 221 results - Relevance
- Date
